Literature DB >> 8664631

Lessons from international experience in controlling pharmaceutical expenditure. I: Influencing patients.

N Freemantle1, K Bloor.   

Abstract

This is the first of three papers to review international policies to control spending on drugs and improve the efficiency of drug use. Policies can target three main groups: patients, prescribing doctors, and the drugs industry. In this paper we examine policies aimed at patients, particularly restrictions on reimbursement (such as prescription charges). Rigorous experimental and quasi-experimental studies suggest that policies to limit the level of reimbursement of drugs reduce the use of essential as well as non-essential drugs and may do more harm than good.

Entities:  

Mesh:

Year:  1996        PMID: 8664631      PMCID: PMC2351214          DOI: 10.1136/bmj.312.7044.1469

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  6 in total

1.  Withdrawing payment for nonscientific drug therapy. Intended and unexpected effects of a large-scale natural experiment.

Authors:  S B Soumerai; D Ross-Degnan; S Gortmaker; J Avorn
Journal:  JAMA       Date:  1990-02-09       Impact factor: 56.272

2.  Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.

Authors:  S B Soumerai; J Avorn; D Ross-Degnan; S Gortmaker
Journal:  N Engl J Med       Date:  1987-08-27       Impact factor: 91.245

3.  Charging for health care: evidence on the utilisation of NHS prescribed drugs.

Authors:  M Ryan; S Birch
Journal:  Soc Sci Med       Date:  1991       Impact factor: 4.634

4.  Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.

Authors:  S B Soumerai; T J McLaughlin; D Ross-Degnan; C S Casteris; P Bollini
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

5.  Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes.

Authors:  S B Soumerai; D Ross-Degnan; J Avorn; T j McLaughlin; I Choodnovskiy
Journal:  N Engl J Med       Date:  1991-10-10       Impact factor: 91.245

6.  Examining product risk in context. Market withdrawal of zomepirac as a case study.

Authors:  D Ross-Degnan; S B Soumerai; E E Fortess; J H Gurwitz
Journal:  JAMA       Date:  1993-10-27       Impact factor: 56.272

  6 in total
  12 in total

1.  Mega-mergers in the pharmaceutical industry. In whose interests?

Authors:  A L Po
Journal:  Pharmacoeconomics       Date:  1998-10       Impact factor: 4.981

Review 2.  Drug rationing in the UK National Health Service. Current status and future prospects.

Authors:  T Walley; A Haycox; S Barton
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

Review 3.  Pharmacy utilization and the Medicare Modernization Act.

Authors:  Vittorio Maio; Laura Pizzi; Adam R Roumm; Janice Clarke; Neil I Goldfarb; David B Nash; David Chess
Journal:  Milbank Q       Date:  2005       Impact factor: 4.911

4.  Prescription charges: change overdue? Britain can learn from systems of copayments based on drugs' effectiveness.

Authors:  T Walley
Journal:  BMJ       Date:  1998-08-22

5.  Could co-payments on drugs help to make EU health care systems less open to political influence?

Authors:  Livio Garattini; Katelijne van de Vooren
Journal:  Eur J Health Econ       Date:  2013-10

6.  The impact of cost-sharing schemes on drug compliance in Italy: evidence based on quantile regression.

Authors:  Vincenzo Atella; Joanna Aleksandra Kopinska
Journal:  Int J Public Health       Date:  2013-12-15       Impact factor: 3.380

Review 7.  Customising an international disease management model to the needs of individual countries. Application to upper gastrointestinal disease.

Authors:  A Haycox; D Dubois; M Butterworth
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 8.  Strategies to improve the cost effectiveness of general practitioner prescribing. An international perspective.

Authors:  H McGavock
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

9.  Drug reimbursement: indicators of inappropriate resource allocation.

Authors:  Bernard Bégaud; Ulf Bergman; Hans-Georg Eichler; Hubert G M Leufkens; Peter J Meier
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 10.  Changing prescribing in the light of tolerability concerns: how is this best achieved?

Authors:  C S de Vries; C A Duggan; T F Tromp; L T de Jong-van den Berg
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.